Should I buy or sell Oncology Institute stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncology Institute in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TOI shares. View TOI analyst ratings or view top-rated stocks .

What is Oncology Institute's stock price target for 2024?

1 brokers have issued 12-month price targets for Oncology Institute's shares. Their TOI share price targets range from $2.00 to $2.50. On average, they expect the company's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price. View analysts price targets for TOI or view top-rated stocks among Wall Street analysts .

How have TOI shares performed in 2024?

Oncology Institute's stock was trading at $2.04 at the beginning of 2024. Since then, TOI shares have decreased by 39.7% and is now trading at $1.23. View the best growth stocks for 2024 here .

When is Oncology Institute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TOI earnings forecast .

What guidance has Oncology Institute issued on next quarter's earnings?

Oncology Institute updated its FY 2024 earnings guidance on Wednesday, March, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.0 million-$415.0 million, compared to the consensus revenue estimate of $378.8 million.

Who are Oncology Institute's major shareholders?

Oncology Institute's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Quattro Financial Advisors LLC (0.08%). Insiders that own company stock include Brad Hively, Havencrest Healthcare Partners, Matthew P Miller, Mohit Kaushal, Richard A Barasch and Richy Agajanian. View institutional ownership trends .

How do I buy shares of Oncology Institute?

Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TOI

Oncology Institute (TOI) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free TOI Stock Alerts

$1.23

+0.06 (+5.13%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.18
▼
$1.28
50-Day Range: $1.16
▼
$2.07
52-Week Range: $0.33
▼
$2.66

Volume: 37,757 shs
Average Volume: 128,107 shs
Market Capitalization: $91.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.25

Get Oncology Institute alerts:

Oncology Institute MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 82.9% Upside
$2.25 Price Target
Short Interest: Healthy
0.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.15
Based on 2 Articles This Week
Insider Trading: Selling Shares
$137,838 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.36) to ($0.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.00 out of 5 stars

Medical Sector

559th out of 918 stocks

Offices & Clinics Of Medical Doctors Industry

4th out of 7 stocks

3.5

Analyst's Opinion

Consensus Rating
Oncology Institute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Oncology Institute has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.84% of the float of Oncology Institute has been sold short.
Short Interest Ratio / Days to Cover
Oncology Institute has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Oncology Institute has recently increased by 12.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Oncology Institute does not currently pay a dividend.
Dividend Growth
Oncology Institute does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TOI.

1.7

News and Social Media Coverage

News Sentiment
Oncology Institute has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Oncology Institute this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for TOI on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
2 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncology Institute insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,838.00 in company stock.
Percentage Held by Insiders
13.10% of the stock of Oncology Institute is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 36.86% of the stock of Oncology Institute is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Oncology Institute are expected to grow in the coming year, from ($0.36) to ($0.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Oncology Institute is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncology Institute is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oncology Institute has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Oncology Institute Stock (NASDAQ:TOI)

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

TOI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TOI Stock News Headlines

April 18, 2024 | msn.com

Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.

April 18, 2024 | markets.businessinsider.com

Topicus.com Inc. Announces Release Date for First Quarter Results

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 10, 2024 | msn.com

Daily healthy habits to reduce cancer risk

April 8, 2024 | finance.yahoo.com

Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute

April 4, 2024 | globenewswire.com

The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California

April 4, 2024 | msn.com

Centre for early cancer detection is gifted £11m

April 2, 2024 | msn.com

Study finds AI empowers patients before and after seeing physicians for radiation oncology treatment

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

April 2, 2024 | msn.com

Man dies after 3 hospitals deny entry in Delhi

April 1, 2024 | finance.yahoo.com

The Oncology Institute, Inc. (NASDAQ:TOI) Q4 2023 Earnings Call Transcript

March 30, 2024 | msn.com

Are we over-looking elderly loneliness?

March 29, 2024 | msn.com

For unity in Covid fight, called for clanging utensils, despite ridicule: PM Modi

March 29, 2024 | finance.yahoo.com

Oncology Institute Full Year 2023 Earnings: US$0.92 loss per share (vs US$0.001 profit in FY 2022)

March 28, 2024 | finance.yahoo.com

Q4 2023 Oncology Institute Inc Earnings Call

March 27, 2024 | benzinga.com

Recap: Oncology Institute Q4 Earnings

March 27, 2024 | finance.yahoo.com

The Oncology Institute Inc (TOI) Reports Mixed Q4 and Full Year 2023 Results

March 27, 2024 | globenewswire.com

The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024

March 24, 2024 | msn.com

Free HPV vaccine given to 135 survivors of sexual abuse

March 24, 2024 | msn.com

Philadelphia College of Osteopathic Medicine and The Wistar Institute Launch Joint Cancer Biology Ph.D. Program

March 23, 2024 | msn.com

Doctors say diagnosis of Princess Catherine’s cancer is a familiar scenario

March 21, 2024 | msn.com

PCOM and The Wistar Institute are launching a cancer biology graduate program

March 20, 2024 | markets.businessinsider.com

PCOM, The Wistar Institute Announce Cancer Biology Graduate Program

March 19, 2024 | msn.com

PGIMER honoured at 5th Entrepreneur and Achiever Award 2024

March 19, 2024 | msn.com

New imaging technology for diagnosing and treating bowel cancer patients

March 15, 2024 | msn.com

Fake cancer drugs racket: Delhi Police arrest IIT grad | All about the case & probe so far

March 14, 2024 | globenewswire.com

MaxHealth & The Oncology Institute Expand Value-Based Care Partnership

See More Headlines

Receive TOI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Offices & clinics of medical doctors
Sub-Industry: N/A
Current Symbol: NASDAQ:TOI
CUSIP: N/A
CIK: 1799191
Web: theoncologyinstitute.com
Phone: 562-735-3226
Fax: N/A
Employees: 750
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.25
High Stock Price Target: $2.50
Low Stock Price Target: $2.00
Potential Upside/Downside: +82.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-83,070,000.00
Net Margins: -24.56%
Pretax Margin: -25.63%
Return on Equity: -80.46%
Return on Assets: -28.14%

Debt

Debt-to-Equity Ratio: 1.52
Current Ratio: 4.12
Quick Ratio: 3.73

Sales & Book Value

Annual Sales: $324.24 million
Price / Sales: 0.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.77 per share
Price / Book: 1.60

Miscellaneous

Outstanding Shares: 74,310,000
Free Float: 64,578,000
Market Cap: $91.40 million
Optionable: Not Optionable
Beta: 0.68

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Richard Alan Barasch (Age 70)
Executive Chairman of the Board
Mr. Mihir Arunkumar Shah CPA (Age 46)
Chief Financial Officer & Principal Accounting Officer
Comp: $393.65k
Ms. Hilda Agajanian M.B.A.
Founder & Chief Growth Officer
Dr. Richy Agajanian M.D.
Founder & Chief Clinical Officer
Mr. Rakesh Singh M.B.A.
Director of Technology
Mr. Mark Hueppelsheuser Esq.
General Counsel
Mr. Khurrum Shah J.D.
M.B.A., Senior Vice President of Compliance
Ms. Julie Korinke
Director of Marketing & Communications
Ms. Laura Szitar
Chief People Officer
Dr. Yale D. Podnos F.A.C.S. (Age 52)
M.D., M.P.H., Chief Medical Officer & President of Practice
Comp: $345.02k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TOI Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncology Institute stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncology Institute in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TOI shares.
View TOI analyst ratings or view top-rated stocks.
What is Oncology Institute's stock price target for 2024?: 1 brokers have issued 12-month price targets for Oncology Institute's shares. Their TOI share price targets range from $2.00 to $2.50. On average, they expect the company's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for TOI or view top-rated stocks among Wall Street analysts.
How have TOI shares performed in 2024?: Oncology Institute's stock was trading at $2.04 at the beginning of 2024. Since then, TOI shares have decreased by 39.7% and is now trading at $1.23.
View the best growth stocks for 2024 here.
When is Oncology Institute's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TOI earnings forecast.

What guidance has Oncology Institute issued on next quarter's earnings?: Oncology Institute updated its FY 2024 earnings guidance on Wednesday, March, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.0 million-$415.0 million, compared to the consensus revenue estimate of $378.8 million.
Who are Oncology Institute's major shareholders?: Oncology Institute's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Quattro Financial Advisors LLC (0.08%). Insiders that own company stock include Brad Hively, Havencrest Healthcare Partners, Matthew P Miller, Mohit Kaushal, Richard A Barasch and Richy Agajanian.
View institutional ownership trends.
How do I buy shares of Oncology Institute?: Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TOI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial